Rubicon Research Limited (NSE: RUBICON) shows pressure after breakout, down 5% intraday at ₹1305.0. The stock, already above resistance, faces profit-taking.
Sai Parenterals Limited's Australian subsidiary, Noumed Pharmaceuticals, renews its exclusive OTC supply agreement with Australia's leading pharmacy networks.
Rubicon Research Limited (NSE: RUBICON) is down 5% intraday at ₹1324.7, showing pressure after breakout. The stock is approaching support at ₹1317.
CORONA Remedies Limited commercialises India's most advanced EU-GMP approved women's hormone manufacturing facility, marking a significant milestone in women.
Marksans Pharma Limited (NSE: MARKSANS) to acquire 100% of QliniQ B.V., enhancing its presence in European markets.
CORONA Remedies Limited (CORONA) secures EU-GMP accreditation for its Hormone and Oral Solid Dosage facilities, boosting its global market expansion.
Marksans Pharma Limited (MARKSANS) reported Q4 & FY26 financial results with historic triple: highest revenue, EBITDA & PAT ₹3,000 Cr.
SMS Pharmaceuticals Limited (SMSPHARMA) reports FY26 PAT up 48% to ₹102 crore, driven by margin expansion and backward integration.
Kopran Limited (KOPRAN) unveils its FY 2025-26 corporate presentation, highlighting significant financial and operational milestones.
Senores Pharmaceuticals Limited (SENORES) reports strong Q4 & FY26 results with revenue up 66% and PAT surge of 219%.